{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T07:58:16Z","timestamp":1782115096959,"version":"3.54.5"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"am","delay-in-days":332,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ejca.2022.04.038","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T12:05:57Z","timestamp":1656504357000},"page":"242-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Practice changing data and emerging concepts from recent radiation therapy randomised clinical trials"],"prefix":"10.1016","volume":"171","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0875-4822","authenticated-orcid":false,"given":"Sophie","family":"Espenel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Chargari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Bockel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.04.038_bib1","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1158\/1078-0432.CCR-19-4155","article-title":"Methodological development of combination drug and radiotherapy in basic and clinical research","volume":"26","author":"Chargari","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.04.038_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.04.038_bib3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.04.038_bib4","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2021.04.015","article-title":"Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01) \u2013 a trans-Tasman radiation oncology group study","volume":"111","author":"Rischin","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2022.04.038_bib5","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1200\/JCO.2017.74.9457","article-title":"Once-a-Week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial","volume":"36","author":"Noronha","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib6","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial","volume":"20","author":"de Boer","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib7","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.ijrobp.2020.10.030","article-title":"Long-term toxicity and health-related quality of life after adjuvant chemoradiation therapy or radiation therapy alone for high-risk endometrial cancer in the randomized PORTEC-3 trial","volume":"109","author":"Post","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2022.04.038_bib8","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer","volume":"380","author":"Matei","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejca.2022.04.038_bib9","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1001\/jamaoncol.2021.2705","article-title":"Efficacy of concurrent chemoradiotherapy with S-1 vs radiotherapy alone for older patients with esophageal cancer: a multicenter randomized phase 3 clinical trial","volume":"7","author":"Ji","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(18)30104-9","article-title":"Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial","volume":"19","author":"Tang","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib11","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S1470-2045(20)30327-2","article-title":"Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study","volume":"21","author":"Sun","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib12","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S1470-2045(19)30326-2","article-title":"NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial","volume":"20","author":"Bonvalot","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib13","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S1470-2045(21)00149-2","article-title":"Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial","volume":"22","author":"Altorki","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib15","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.eururo.2020.07.032","article-title":"Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors","volume":"78","author":"Fizazi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2022.04.038_bib16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1200\/JCO.20.00290","article-title":"Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma","volume":"39","author":"McBride","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2022.04.038_bib17","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001001","article-title":"Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I\/II trial","volume":"8","author":"Welsh","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2022.04.038_bib19","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ejca.2022.04.038_bib20","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","article-title":"Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial","volume":"4","author":"Yoon","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2017.73.7718","article-title":"Effect of neoadjuvant chemoradiotherapy on health-related quality of life in esophageal or junctional cancer: results from the randomized CROSS trial","volume":"36","author":"Noordman","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib22","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.20.03614","article-title":"Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib23","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","article-title":"Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial","volume":"36","author":"Yang","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejca.2020.08.002","article-title":"Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010","volume":"138","author":"Liu","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.04.038_bib25","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib26","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1001\/jamaoncol.2020.1808","article-title":"Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial","volume":"6","author":"You","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib27","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.04.038_bib28","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib29","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1200\/JCO.20.03697","article-title":"Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO study)","volume":"39","author":"Hulshof","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib30","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(20)30742-7","article-title":"High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial","volume":"22","author":"Gr\u00f8nberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib32","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1470-2045(21)00076-0","article-title":"Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis","volume":"22","author":"Petit","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib33","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.038_bib34","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib36","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(21)01123-5","article-title":"Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"398","author":"Chen","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.04.038_bib37","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1200\/JCO.18.02158","article-title":"Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG oncology RTOG 0521 trial","volume":"37","author":"Rosenthal","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib38","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","author":"Attard","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.04.038_bib39","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jamaoncol.2019.1146","article-title":"Afatinib vs placebo as adjuvant therapy after chemoradiotherapy in squamous cell carcinoma of the head and neck: a randomized clinical trial","volume":"5","author":"Burtness","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib40","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.038_bib41","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jtho.2020.12.015","article-title":"Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial","volume":"16","author":"Faivre-Finn","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib42","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.038_bib43","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.04.038_bib44","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib45","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib46","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(20)30013-9","article-title":"Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial","volume":"21","author":"Nestle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib47","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.04.038_bib48","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1200\/JCO.20.00935","article-title":"Consolidation radiotherapy could Be safely omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD: final analysis of the randomized GITIL\/FIL HD0607 trial","volume":"38","author":"Gallamini","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib49","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib50","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.radonc.2004.12.015","article-title":"Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV","volume":"74","author":"Haie-Meder","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib51","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","article-title":"Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial","volume":"20","author":"Carrie","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib52","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.19.02444","article-title":"Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer","volume":"38","author":"Chera","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib53","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.04.038_bib54","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1470-2045(21)00090-5","article-title":"Adjuvant and concurrent temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study","volume":"22","author":"van den Bent","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib55","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.20.03128","article-title":"Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG oncology HN002)","volume":"39","author":"Yom","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib56","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1001\/jamaoncol.2018.2583","article-title":"Association of transforming growth factor \u03b2 polymorphism C-509T with radiation-induced fibrosis among patients with early-stage breast cancer: a secondary analysis of a randomized clinical trial","volume":"4","author":"Grossberg","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib57","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1001\/jamaoncol.2021.3186","article-title":"Accelerated hypofractionated image-guided vs conventional radiotherapy for patients with stage II\/III non-small cell lung cancer and poor performance status: a randomized clinical trial","volume":"7","author":"Iyengar","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib58","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1200\/JCO.20.01363","article-title":"Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO trial","volume":"38","author":"Offersen","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib59","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.radonc.2020.02.018","article-title":"Acute radiation-induced skin toxicity in hypofractionated vs. conventional whole-breast irradiation: an objective, randomized multicenter assessment using spectrophotometry","volume":"146","author":"Schmeel","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib60","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1470-2045(18)30813-1","article-title":"Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial","volume":"20","author":"Wang","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib61","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","volume":"395","author":"Murray Brunt","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.04.038_bib62","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1200\/JCO.19.02750","article-title":"Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer","volume":"38","author":"Brunt","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib63","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1200\/JCO.20.00650","article-title":"Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial","volume":"38","author":"Meattini","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib64","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/S0140-6736(19)32515-2","article-title":"External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial","volume":"394","author":"Whelan","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.04.038_bib65","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/S0140-6736(19)32514-0","article-title":"Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial","volume":"394","author":"Vicini","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.04.038_bib66","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1200\/JCO.19.01485","article-title":"Ten-year update of a randomized, prospective trial of conventional fractionated versus moderate hypofractionated radiation therapy for localized prostate cancer","volume":"38","author":"Avkshtol","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib67","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.04.038_bib68","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib69","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijrobp.2020.01.022","article-title":"Erectile dysfunction and absorbed dose to penile base structures in a randomized trial comparing ultrahypofractionated and conventionally fractionated radiation therapy for prostate cancer","volume":"107","author":"Rasmusson","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2022.04.038_bib70","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(20)30581-7","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial","volume":"22","author":"Fransson","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib71","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1470-2045(20)30686-0","article-title":"4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial","volume":"22","author":"Hoskin","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib72","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.18.01575","article-title":"Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel\/carboplatin in high-intermediate and high-risk early stage endometrial cancer","volume":"37","author":"Randall","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib73","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib74","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib75","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.04.038_bib76","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.04.038_bib77","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1470-2045(20)30673-2","article-title":"Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Liu","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib78","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S1470-2045(20)30446-0","article-title":"Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Bonvalot","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib79","article-title":"Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial","author":"Le Pechoux","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib80","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaoncol.2021.1910","article-title":"Effect of postoperative radiotherapy for patients with pIIIA-N2 non-small cell lung cancer after complete resection and adjuvant chemotherapy: the phase 3 PORT-C randomized clinical trial","volume":"7","author":"Hui","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib81","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/jamaoncol.2018.7220","article-title":"Prophylactic cranial irradiation vs observation in patients with locally advanced non-small cell lung cancer: a long-term update of the NRG oncology\/RTOG 0214 phase 3 randomized clinical trial","volume":"5","author":"Sun","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib82","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1200\/JCO.2017.77.5817","article-title":"Prophylactic cranial irradiation versus observation in radically treated stage III non-small-cell lung cancer: a randomized phase III NVALT-11\/DLCRG-02 study","volume":"36","author":"De Ruysscher","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib83","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1001\/jamaoncol.2020.2394","article-title":"Association of treatment adherence with oncologic outcomes for patients with rectal cancer: a post hoc analysis of the CAO\/ARO\/AIO-04 phase 3 randomized clinical trial","volume":"6","author":"Diefenhardt","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib84","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.annonc.2020.06.012","article-title":"Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial","volume":"31","author":"Glynne-Jones","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib85","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1470-2045(18)30195-5","article-title":"Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial","volume":"19","author":"Sch\u00e4fer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib86","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1200\/JCO.21.01083","article-title":"Randomized phase III trial evaluating radiation following surgical excision for good-risk ductal carcinoma in situ: long-term report from NRG oncology\/RTOG 9804","volume":"39","author":"McCormick","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib87","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO.2017.77.4273","article-title":"Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG oncology-RTOG 1203","volume":"36","author":"Klopp","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib88","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1200\/JCO.19.02381","article-title":"Improvement in patient-reported outcomes with intensity-modulated radiotherapy (RT) compared with standard RT: a report from the NRG oncology RTOG 1203 study","volume":"38","author":"Yeung","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib89","first-page":"JCO2002530","article-title":"Late toxicity after adjuvant conventional radiation versus image-guided intensity-modulated radiotherapy for cervical cancer (PARCER): a randomized controlled trial","author":"Chopra","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib90","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1200\/JCO.21.00639","article-title":"Randomized phase III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small-cell lung cancer (PREMER): a GICOR-GOECP-SEOR study","volume":"39","author":"Rodr\u00edguez de Dios","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib91","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/JCO.19.02767","article-title":"Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001","volume":"38","author":"Brown","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib92","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jtho.2020.12.024","article-title":"Phase 3 randomized trial of prophylactic cranial irradiation with or without hippocampus avoidance in SCLC (NCT01780675)","volume":"16","author":"Belderbos","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib93","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.6186","article-title":"Effects of surgery with salvage stereotactic radiosurgery versus surgery with whole-brain radiation therapy in patients with one to four brain metastases (JCOG0504): a phase III, noninferiority, randomized controlled trial","author":"Kayama","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib94","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S1470-2045(20)30472-1","article-title":"Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922\/10925): 15-year results of a randomised, phase 3 trial","volume":"21","author":"Poortmans","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib95","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1200\/JCO.19.02503","article-title":"Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib96","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1200\/JCO.2017.74.0720","article-title":"Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer","volume":"36","author":"Liao","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib97","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2019.0192","article-title":"Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: a randomized phase 2 trial","volume":"5","author":"Nguyen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib98","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.ijrobp.2020.09.019","article-title":"CCTG SC.24\/TROG 17.06: a randomized phase II\/III study comparing 24Gy in 2 stereotactic body radiotherapy (SBRT) fractions versus 20Gy in 5 conventional palliative radiotherapy (CRT) fractions for patients with painful spinal metastases","volume":"108","author":"Sahgal","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2022.04.038_bib99","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ijrobp.2020.05.021","article-title":"Patient perceptions in a nonblinded randomized trial of radiation therapy technologies: a novel survey study exploring therapeutic misconception","volume":"108","author":"Shumway","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2022.04.038_bib100","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ijrobp.2020.06.002","article-title":"Urethra-sparing stereotactic body radiation therapy for prostate cancer: quality assurance of a randomized phase 2 trial","volume":"108","author":"Jaccard","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2022.04.038_bib101","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.ijrobp.2021.01.055","article-title":"Investigation of relation of radiation therapy quality with toxicity and survival in LAP07 phase 3 trial for locally advanced pancreatic carcinoma","volume":"110","author":"Giraud","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2022.04.038_bib102","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jrr\/rraa085","article-title":"A dummy-run evaluation of postoperative hypofractionated intensity-modulated radiation therapy (POHIM-RT) trials for cervical cancer","volume":"62","author":"Cho","year":"2021","journal-title":"J Radiat Res"},{"key":"10.1016\/j.ejca.2022.04.038_bib103","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.adro.2020.05.005","article-title":"Offline quality assurance for intensity modulated radiation therapy treatment plans for NRG-HN001 head and neck clinical trial using knowledge-based planning","volume":"5","author":"Giaddui","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ejca.2022.04.038_bib104","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ijrobp.2020.04.042","article-title":"Central review of radiation therapy planning among patients with breast-conserving surgery: results from a quality assurance process integrated into the INSEMA trial","volume":"107","author":"Hildebrandt","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2022.04.038_bib105","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.canrad.2021.04.005","article-title":"A priori quality assurance using a benchmark case of the randomized phase 2 GORTEC 2014-14 in oligometastatic head and neck cancer patients","volume":"25","author":"Khalladi","year":"2021","journal-title":"Cancer Radiother"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922002787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922002787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:38:30Z","timestamp":1760733510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922002787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":105,"alternative-id":["S0959804922002787"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.04.038","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practice changing data and emerging concepts from recent radiation therapy randomised clinical trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.04.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}